Pharma channel feed – Endpoints News

Pharma channel feed

Taking on a big challenge, ex-Celgene CEO Bob Hugin readies a run for the Senate

8 years ago

What's the trouble with pain? Analysis shows scarce investments, high failure rate for new drugs

8 years ago

Once rejected, FDA now rolls out a short red carpet for Amicus’ migalastat

8 years ago

What's he thinking about? Vivek Ramaswamy lines up a heavyweight title fight for a late-stage diabetes drug

8 years ago

Market crash slumps biotech as investors yank $1.2B from funds

8 years ago

Seattle Genetics seeds a new immuno-oncology collaboration with the protein explorers at Pieris

8 years ago

In latest blow to Teva, CGRP migraine med could be delayed while rivals race towards the finish line

8 years ago

Gilead gets a blockbuster boost from an FDA OK of HIV triplet Biktarvy — and rival GSK fires back

8 years ago

Verastem takes AbbVie’s blood cancer castoff to the FDA

8 years ago

J&J antes up on a $1B gamble that Theravance has the next blockbuster JAK for Crohn’s, ulcerative colitis

8 years ago

Zogenix wins inside track at FDA with childhood epilepsy ‘breakthrough’

8 years ago

The Endpoints 100: Biotech execs stampede into 2018 with a cheer for the FDA and bullish feelings on public markets, private investors and a ‘hot’ M&A future

8 years ago

Slammed by a trial hold, Intarcia terminates studies and axes staff in wake of an FDA rejection

8 years ago

Amgen’s $70B in ‘deal capacity’ post-tax reform puts the spotlight on 'big things' in M&A — analyst

8 years ago

AstraZeneca sweeps out a PhIII asthma flop, a PD-1 drug and some other rejects as Q4 tally disappoints

8 years ago

After EMA flop, Puma takes Nerlynx to China in new out-licensing deal

8 years ago

Nuclear scare to fuel anti-radiation drug sales? PTx buys ex-Sanofi drug just in case

8 years ago

Counting its remaining cash, Vical axes 40 staffers and circles wagons around two Phase II assets

8 years ago

Eyeing a multibillion-dollar market, Shire snags preclinical IVIg rival from AB Biosciences

8 years ago

Suspicious returns trigger insider trading suit following $11.6B Bioverativ deal

8 years ago

Roche scores an unusual ‘breakthrough’ at the FDA for an autism drug

8 years ago

In post-IPO party, Nasdaq’s newcomers Armo, Menlo and Solid soar within hours of listing

8 years ago

Novartis scores a quick FDA OK for its new cancer drug Lutathera, picked up in $4B buyout

8 years ago

Under pressure to perform, Woodford counterattacks against Sahm Adrangi's latest short assault

8 years ago

First page Previous page 306 307 308309310 311 312 Next page Last page